Virtu Financial LLC bought a new position in NuCana plc (NASDAQ:NCNA – Free Report) during the fourth quarter, Holdings Channel.com reports. The firm bought 40,399 shares of the company’s stock, valued at approximately $48,000.
NuCana Stock Performance
Shares of NuCana stock opened at $0.89 on Wednesday. The stock has a market capitalization of $2.35 million, a P/E ratio of -0.08 and a beta of 0.89. The stock’s 50-day simple moving average is $0.94 and its 200 day simple moving average is $1.43. NuCana plc has a 52-week low of $0.69 and a 52-week high of $10.79.
NuCana (NASDAQ:NCNA – Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.43) by $2.11. Equities research analysts forecast that NuCana plc will post -13.42 EPS for the current fiscal year.
NuCana Profile
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.
Featured Articles
- Five stocks we like better than NuCana
- Following Congress Stock Trades
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- Business Services Stocks Investing
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Buffett Trims Equities, But Still Keeps Buying This Stock
Want to see what other hedge funds are holding NCNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuCana plc (NASDAQ:NCNA – Free Report).
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.